Raymond James & Associates Has $180.80 Million Position in Zoetis Inc. (NYSE:ZTS)

Raymond James & Associates boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 16.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 925,354 shares of the company’s stock after purchasing an additional 130,935 shares during the quarter. Raymond James & Associates owned 0.20% of Zoetis worth $180,796,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ZTS. Vanguard Group Inc. grew its position in shares of Zoetis by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after acquiring an additional 414,605 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Zoetis by 4.0% during the second quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock worth $812,695,000 after acquiring an additional 178,303 shares during the period. Capital Research Global Investors boosted its holdings in shares of Zoetis by 2.3% during the first quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock worth $685,416,000 after acquiring an additional 90,330 shares during the period. Clearbridge Investments LLC boosted its holdings in shares of Zoetis by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock worth $527,774,000 after acquiring an additional 166,517 shares during the period. Finally, Sarasin & Partners LLP boosted its holdings in shares of Zoetis by 546.3% during the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after acquiring an additional 1,904,899 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $193.28 on Friday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a market cap of $87.57 billion, a price-to-earnings ratio of 37.82, a PEG ratio of 3.00 and a beta of 0.89. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The firm’s 50-day simple moving average is $188.98 and its 200 day simple moving average is $177.07.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter last year, the firm earned $1.41 EPS. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, research analysts anticipate that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.89%. Zoetis’s dividend payout ratio (DPR) is 33.86%.

Analyst Ratings Changes

Several research firms have weighed in on ZTS. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.